These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16418498)

  • 1. Prognostic biomarkers in diffuse large B-cell lymphoma.
    Lossos IS; Morgensztern D
    J Clin Oncol; 2006 Feb; 24(6):995-1007. PubMed ID: 16418498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
    Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
    J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma.
    Wu G; Keating A
    Cancer; 2006 Jan; 106(2):247-57. PubMed ID: 16342164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
    Shipp MA; Ross KN; Tamayo P; Weng AP; Kutok JL; Aguiar RC; Gaasenbeek M; Angelo M; Reich M; Pinkus GS; Ray TS; Koval MA; Last KW; Norton A; Lister TA; Mesirov J; Neuberg DS; Lander ES; Aster JC; Golub TR
    Nat Med; 2002 Jan; 8(1):68-74. PubMed ID: 11786909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
    Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
    Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.
    Seshadri T; Kuruvilla J; Crump M; Keating A
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):259-67. PubMed ID: 18275892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathogenesis of diffuse large B-cell lymphoma.
    Lossos IS
    J Clin Oncol; 2005 Sep; 23(26):6351-7. PubMed ID: 16155019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
    Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
    Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional survival of patients with diffuse large B-cell lymphoma.
    Moller MB; Pedersen NT; Christensen BE
    Cancer; 2006 May; 106(10):2165-70. PubMed ID: 16586498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
    Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
    Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited.
    Segal MR
    Biostatistics; 2006 Apr; 7(2):268-85. PubMed ID: 16284340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
    Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
    APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas.
    Shim HK; Lee WW; Park SY; Kim H; So Y; Kim SE
    Nucl Med Biol; 2009 Feb; 36(2):191-7. PubMed ID: 19217531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diagnosis of lymphoma: outcome prediction by gene expression profiling in diffuse large B-cell lymphoma.
    Last K; Debarnardi S; Lister TA
    Methods Mol Med; 2005; 115():15-63. PubMed ID: 15998962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas.
    Ramuz O; Bouabdallah R; Devilard E; Borie N; Groulet-Martinec A; Bardou VJ; Brousset P; Bertucci F; Birg F; Birnbaum D; Xerri L
    Int J Oncol; 2005 Jan; 26(1):151-7. PubMed ID: 15586235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.